Drug Designing: Open Access
Open Access

Synthesis and pharmacological activities of some novel N, N disubstituted urea derivatives

2^nd International Conference and Expo on Drug Discovery & Designing

October 27-29, 2016 Rome, Italy

Hulya Akgun, Bengisu Turgutalp, Hande Sipahi, Beril Kadioglu and Inci Deniz

Yeditepe University, Turkey

Posters & Accepted Abstracts: Drug Des

Abstract :

Cancer is a major worldwide health problem. The current treatments for cancer include surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, hormone therapy and stem cell transplant. Chemotherapy has been a cornerstone treatment among these therapies. Thereof, the development of more efficient and less toxic anticancer agents is still an ongoing area of interest. Various proteins and enzymes play significant role in such processes as cell growth, metabolism, apoptosis and inflammation. Protein kinase is an important enzyme family among various proteins and enzymes that plays significant role in processes such as cell growth, metabolism, apoptosis and inflammation. Therefore synthesizing molecules that inhibit protein kinases has been an attractive area in pharmaceutical industry. Imatinib (Gleevec�?®) is the first protein kinase inhibitor which entered clinical use in early 2000s and over a hundred protein kinase inhibitors have reached to advanced clinical trials over the last decade. N, N'disubstituted ureas are a class of protein-kinase inhibitor. Sorafenib is one of the many structurally diverse multi-kinase inhibitors. It is approved by Food and Drug Administration (FDA) for hepatocellular carcinoma (HCC) and metastatic renal cell carcinoma (MRCC). Linifanib (ABT-869), in clinical trials, is an another potent inhibitor of receptor tyrosine kinases (RTK), vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). Doramapimod (BIRB 796), N-pyrazole-N'-naphthyl urea compound with strong p38 mitogen-activated protein kinase (MAPK) inhibitor activity, has been developed for mitigating rheumatoid arthritis and Crohnâ�?�?s disease. The aim of this study is to synthesize new diarylurea derivatives that may possess inhibitor effect on many kinases and are structurally similar to sorafenib.

Biography :

Email: hakgun@yeditepe.edu.tr